专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

【2】北京部分高校体育场馆暑期面向社会开放 暑期来临，部分高校的游泳馆体育馆陆续开放，这不仅是学子们的运动天地，更是服务市民的优质公共 资源，场馆设施专业、空间充裕、管理规范，为大家夏日健身提供了安全舒适的新选择。 【1】教育部发布2025年第2号留学预警 7月18日，教育部发布消息，近期，菲律宾治安不靖，针对中国公民犯罪多发。教育部提醒广大留学人 员，近期选择赴菲学习时做好安全风险评估，增强防范意识。 【4】学大教育子公司终止2.14亿元收购岳阳育盛项目 7月18日，学大教育发布公告，公司决定终止对外投资项目。根据公告，公司下属全资子公司学大信息 原计划收购岳阳育盛教育投资有限公司90%股权，交易对价为2.14亿元，然而由于相关方未满足付款条 件及其他先决条件，公司经过综合考量后与相关各方签署了解除协议，正式终止该投资项目。截至本公 告披露日，公司未实际出资。 【5】ST东时对参股子公司定向减资1200万元 7月18日，ST东时发布公告，公司对参股子公司乌鲁木齐城投东方时尚智行科技有限公司定向减少注册 资本1200万元，减资部分为公司尚未实缴的注册资本，不会损害公司及中小股东利益。减资后，东方时 尚智行科技 ...

Group 1 - The Yarlung Tsangpo River downstream hydropower project has officially commenced with a total investment of approximately 1.2 trillion yuan, aiming to build five tiered power stations primarily for electricity transmission and local consumption in Tibet [1] - The Ministry of Industry and Information Technology (MIIT) plans to accelerate the development of biomanufacturing and low-altitude industries, while promoting innovation in future industries such as humanoid robots and brain-computer interfaces [2][3] - The MIIT and the National Development and Reform Commission (NDRC) are set to issue work plans to stabilize growth in key industries including steel, non-ferrous metals, petrochemicals, and building materials [2][3] Group 2 - The U.S. Department of Commerce has imposed a preliminary anti-dumping duty of 93.5% on Chinese imported anode-grade graphite, citing unfair subsidies [5] - The State Administration for Market Regulation has urged major platform companies like Ele.me, Meituan, and JD.com to standardize promotional activities and foster a healthy competitive environment in the food service industry [6] - A meeting was held to discuss the regulation of the new energy vehicle industry, focusing on enhancing supervision and monitoring product prices and quality [8] Group 3 - The China Iron and Steel Association has proposed a new mechanism for capacity governance to prevent overcapacity risks in the steel industry and to eliminate irrational competition [10] - Yu Shu Technology has initiated its listing guidance, with its controlling shareholder holding approximately 34.76% of the company's shares [11] - Multiple provinces are planning to establish companies to develop local cultural creative Moutai liquor, with participation from distributors based on their allocation of Moutai products [12] Group 4 - As of July 18, 1551 A-share listed companies have released performance forecasts for the first half of 2025, with 26 companies expecting a net profit increase of over 1000% year-on-year [14] - Longhua Automobile reported a net profit of 6.337 billion yuan for the first half of the year, reflecting a year-on-year decline of 10.22% [19] - The major shareholder of Hongbaoli plans to reduce its stake by up to 2% [20]

Core Viewpoint - The company has announced a cash dividend distribution plan for the fiscal year 2024, with a total cash dividend amounting to 24,946,612.40 RMB, distributing 0.50 RMB per 10 shares to all shareholders [1][2][3]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 0.50 RMB per 10 shares (including tax) to all shareholders, with no stock dividends or capital reserve transfers [2][3]. - The total cash dividend amount is calculated based on the total share capital of 498,932,248 shares, resulting in a total distribution of 24,946,612.40 RMB [1][5]. Ex-Dividend Price Adjustment - The ex-dividend price will be adjusted by subtracting 0.0486609 RMB per share from the closing price on the trading day before the ex-dividend date [2][6]. - The adjusted ex-dividend price will affect the ongoing stock options, changing the exercise price from 6.24 RMB to 6.19 RMB per share [6]. Dividend Payment Dates - The record date for the dividend distribution is set for July 24, 2025, and the ex-dividend date is July 25, 2025 [3][4]. Eligible Shareholders - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [4]. Taxation on Dividends - Different tax rates will apply based on the type of shares held, with specific provisions for Hong Kong investors and domestic investors regarding the withholding of individual income tax [3].

证券代码：002728 证券简称：特一药业 公告编号：2025-051 特一药业集团股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度利润分配方案为：以公司现有总股本 512,661,866 股剔除已回购 股份 13,729,618 股后的股本 498,932,248 股为基数，按分配比例不变的原则，向全体 股东每 10 股派发现金红利 0.500000 元（含税），不送红股，不以公积金转增股本。 2、鉴于公司回购专户上的股份不参与 2024 年度权益分派，公司本次实际现金分红 的总金额为 24,946,612.40 元（实际现金分红的总金额=实际参与分配的总股本×每股 分配比例，即 24,946,612.40 元=498,932,248 股×0.0500000 元/股）。因公司已购回 的股份不参与分红，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一 股的比例将减小。因此，本次权益分派实施后除权除息价格计算时，按公司总股本（含 回购专户股份）折算的每股现金红利应以 0. ...

Core Points - The Nomination Committee of the Board of Directors of Te Yi Pharmaceutical Group Co., Ltd. has reviewed the qualifications of the proposed senior management personnel and found them to meet the necessary criteria for their roles [1][2] - The proposed senior management candidates have not faced any penalties from the China Securities Regulatory Commission or other relevant authorities, nor have they been subject to any criminal investigations or violations [1] - Ms. Xu Zilan has been nominated as the Secretary of the Board and possesses the necessary qualifications and professional capabilities for the role, including a recognized Secretary qualification certificate from the Shenzhen Stock Exchange [1][2] Summary by Sections - **Nomination Process**: The nomination process for the senior management personnel has complied with the Company Law and relevant regulations, with the candidates' consent obtained [1] - **Qualifications of Candidates**: The proposed candidates for senior management roles have the required qualifications and capabilities to fulfill their responsibilities effectively [1] - **Specific Nomination**: The Nomination Committee has agreed to appoint Mr. Xu Ronghuang, Mr. Chen Xiliang, Mr. Zhang Yongzhao, Mr. Wu Weicheng, Mr. Yan Wenge, and Mr. Xu Rongjun as senior management, and Ms. Xu Zilan as the Secretary of the Board [2]

Group 1 - The company held its second extraordinary general meeting of shareholders on July 16, 2025, where five non-employee representative directors were elected to form the sixth board of directors [1] - The sixth board consists of six directors, including four non-independent directors and two independent directors, with the term lasting three years from the date of approval [1][2] - The board's composition meets regulatory requirements regarding the proportion of independent directors and the qualifications of independent director candidates have been approved by the Shenzhen Stock Exchange [1][2] Group 2 - The company appointed senior management personnel, including the general manager, deputy general managers, and the head of the audit department, all for a term of three years [2][3] - The general manager is Mr. Xu Ronghuang, with Mr. Chen Xiliang serving as the deputy general manager and financial director [2][3] - The company’s secretary of the board and securities affairs representative have obtained the necessary qualifications as per regulatory requirements [3] Group 3 - Following the board re-election, Mr. Xu Danqing and Mr. Xu Songqing stepped down from their respective positions but will continue to work within the company [4][5] - Mr. Xu Danqing holds 139,973,400 shares, accounting for 27.30% of the total share capital, while Mr. Xu Songqing holds 40,572,000 shares, representing 7.91% [4][5] - The company expressed gratitude for the contributions made by the departing directors during their tenure [5] Group 4 - The resumes of the newly appointed directors and senior management personnel are available in the attachment, detailing their qualifications and professional backgrounds [5][6] - Mr. Xu Ronghuang, the chairman, has been with the company since 2015 and has held various positions before becoming the general manager [6][13] - The independent directors, including Ms. Zhao Xiaobo and Mr. Lai Hanqi, have no conflicts of interest with major shareholders or other directors [11][12]

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shenzhen) confirms that the adjustment of the exercise price for the 2021 stock option incentive plan of Te Yi Pharmaceutical Group Co., Ltd. has obtained the necessary approvals and complies with relevant regulations [1][4][5]. Group 1: Approval and Authorization - The board of directors has authorized the adjustment of the exercise price for the stock option incentive plan, which is now set at 6.19 yuan per share [4][5]. - The adjustment is deemed to be in accordance with the provisions of the stock incentive plan and relevant regulations [4][5]. Group 2: Specifics of the Adjustment - The adjustment was necessitated by a cash dividend distribution of 0.50 yuan per 10 shares, with no stock dividends or capital increases [4][5]. - The formula used for the adjustment of the exercise price is P = P0 - V, where P0 is the original exercise price, V is the cash dividend per share, and P is the adjusted exercise price [5]. - Following the adjustment, the exercise price changed from 6.24 yuan per share to 6.19 yuan per share [5]. Group 3: Conclusion - The legal opinion concludes that the adjustment has received the necessary approvals and is in compliance with the relevant laws and regulations [5][6]. - The company is required to fulfill its information disclosure obligations and complete the necessary procedures related to this adjustment [5].

证券代码：002728 证券简称：特一药业 公告编号：2025-050 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 7 月 16 日召开第六届董事会第一次会议，审议通过了《关于调整 2021 年股票期权激励计划 股票期权行权价格的议案》，现就调整相关事宜公告如下： 一、2021 年股票期权激励计划基本情况 1、2021 年 10 月 12 日，公司召开第四届董事会第二十一次会议，审议通过了《关 于公司<2021 年股票期权激励计划（草案）>及其摘要的议案》《关于公司<2021 年股票 期权激励计划实施考核管理办法>的议案》及《关于提请股东会授权董事会办理 2021 年股票期权激励计划有关事项的议案》。 2、2021 年 10 月 12 日，公司召开第四届监事会第二十一次会议，审议通过了《关 于公司<2021 年股票期权激励计划（草案）>及其摘要的议案》《关于公司<2021 年股票 期权激励计划实施考核管理办法>的议案》及《关于核实<公司 2021 年股票期权激励计 划激励对象名单>的议案》。 3、2021 年 10 月 13 日至 2021 年 10 月 22 日，公司对激励对 ...

国浩律师（深圳）事务所 关 于 法律意见书 深圳市福田区深南大道 6008 号特区报业大厦 42、41、31DE、2403、2405 电话（Tel.）：(+86)(755)8351 5666 传真（Fax.）：(+86)(755)8351 5333/8351 5090 网站（Website）：http://www.grandall.com.cn 2025 年 7 月 特一药业集团股份有限公司 2021 年股票期权激励计划调整行权价格 的 国浩律师（深圳）事务所 关于特一药业集团股份有限公司 2021 年股票期权激励计划 调整行权价格的法律意见书 GLG/SZ/A2957/FY/2025-878 致：特一药业集团股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受特一药业集团股份有限公司（以 下简称"公司"或"特一药业"）的委托，担任特一药业 2021 年股票期权激励计划（以 下简称"本次激励计划"）的专项法律顾问，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司股权激励管理办法》（以下简称"《管理办法》"）等法律、法规和规范性文 ...